Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to his Oral Statement of 11 December 2024 on Puberty-suppressing Hormones, Official Report, column 914-916, whether the clinical trial into the use of puberty suppressing hormones for gender incongruence will begin early this year; and when his Department intends to update parents and young people on the (a) timetable and (b) eligibility of the clinical trial.

The PATHWAYS study proposal, including the clinical trial of puberty-suppressing hormones, is going through all the usual review and approval stages. These include an independent academic peer review and consideration by the National Institute for Health and Care Research’s funding committee. The study will need to secure full ethical approval before it can be set up and recruitment can open. The design of the study, including the timetable and eligibility criteria, will be finalised as part of the approvals process. It is planned to commence this year. Subject to the study achieving the necessary approvals, the study protocol will be made available in the public domain, as is usual for publicly funded studies.